Characterization of COVID-19 Hospitalized Patients in Three United States Electronic Health Record Databases

被引:2
|
作者
Saunders-Hastings, Patrick [1 ]
Zhou, Cindy Ke [2 ]
Hobbi, Shayan [3 ]
Boyd, Eva [1 ]
Lloyd, Patricia [2 ]
Alawar, Nader [3 ]
Burrell, Timothy [3 ]
Beers, Jeff [3 ]
Clarke, Tainya C. C. [2 ]
Hettinger, Aaron Z. Z. [4 ]
Wong, Hui-Lee [2 ]
Shoaibi, Azadeh [2 ]
机构
[1] Gev Consulting Inc, Ottawa, ON K1P 1A4, Canada
[2] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA
[3] IBM Consulting, Bethesda, MD 20814 USA
[4] MedStar Hlth Res Inst, Ctr Biostat Informat & Data Sci, Hyattsville, MD 20782 USA
来源
PATHOGENS | 2023年 / 12卷 / 03期
关键词
COVID-19; hospitalization; EHR; epidemiology; treatment; United States; EPIDEMIOLOGY; OUTCOMES; ADULTS;
D O I
10.3390/pathogens12030390
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
COVID-19 infections have contributed to substantial increases in hospitalizations. This study describes demographics, baseline clinical characteristics and treatments, and clinical outcomes among U.S. patients admitted to hospitals with COVID-19 during the prevaccine phase of the pandemic. A total of 20,446 hospitalized patients with a positive COVID-19 nucleic acid amplification test were identified from three large electronic health record databases during 5 February-30 November 2020 (Academic Health System: n = 4504; Explorys; n = 7492; OneFlorida: n = 8450). Over 90% of patients were >= 30 years of age, with an even distribution between sexes. At least one comorbidity was recorded in 84.6-96.1% of patients; cardiovascular and respiratory conditions (28.8-50.3%) and diabetes (25.6-44.4%) were most common. Anticoagulants were the most frequently reported medications on or up to 28 days after admission (44.5-81.7%). Remdesivir was administered to 14.1-24.6% of patients and increased over time. Patients exhibited higher COVID-19 severity 14 days following admission than the 14 days prior to and on admission. The length of in-patient hospital stay ranged from a median of 4 to 6 days, and over 85% of patients were discharged alive. These results promote understanding of the clinical characteristics and hospital-resource utilization associated with hospitalized COVID-19 over time.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Health outcomes and economic burden of hospitalized COVID-19 patients in the United States
    Di Fusco, Manuela
    Shea, Kimberly M.
    Lin, Jay
    Nguyen, Jennifer L.
    Angulo, Frederick J.
    Benigno, Michael
    Malhotra, Deepa
    Emir, Birol
    Sung, Anita H.
    Hammond, Jennifer L.
    Stoychev, Sophia
    Charos, Apostolos
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 308 - 317
  • [2] Clinical characteristics of pediatric patients hospitalized with COVID-19 in an electronic health record database
    Chomistek, Andrea K.
    Doherty, Michael C.
    Gately, Robert V.
    Ogilvie, Rachel P.
    Liang, Caihua
    Seeger, John D.
    Wang, Florence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 169 - 170
  • [3] Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
    Lianne Barnieh
    Rachel Beckerman
    Sushanth Jeyakumar
    Alice Hsiao
    James Jarrett
    Robert L. Gottlieb
    Infectious Diseases and Therapy, 2023, 12 : 1655 - 1665
  • [4] Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
    Barnieh, Lianne
    Beckerman, Rachel
    Jeyakumar, Sushanth
    Hsiao, Alice
    Jarrett, James
    Gottlieb, Robert L.
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (06) : 1655 - 1665
  • [5] Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States
    Choong, Casey Kar-Chan
    Belger, Mark
    Koch, Alisa E.
    Meyers, Kristin J.
    Marconi, Vincent C.
    Abedtash, Hamed
    Faries, Douglas
    Krishnan, Venkatesh
    ADVANCES IN THERAPY, 2022, 39 (10) : 4723 - 4741
  • [6] Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States
    Casey Kar-Chan Choong
    Mark Belger
    Alisa E. Koch
    Kristin J. Meyers
    Vincent C. Marconi
    Hamed Abedtash
    Douglas Faries
    Venkatesh Krishnan
    Advances in Therapy, 2022, 39 : 4723 - 4741
  • [7] Electronic health record data shows immunosuppressive conditions are associated with poor outcomes in patients hospitalized for COVID-19
    Guggilla, Vijeeth
    Pacheco, Jennifer
    Carvalho, Alexandre
    Pawlowski, Anna
    Whitmer, Grant
    Achenbac, Chad
    Walunas, Theresa
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [8] Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study
    Liang, Caihua
    Ogilvie, Rachel P.
    Doherty, Michael
    Clifford, C. Robin
    Chomistek, Andrea K.
    Gately, Robert
    Song, Jennifer
    Enger, Cheryl
    Seeger, John
    Lin, Nancy D.
    Wang, Florence T.
    PLOS ONE, 2022, 17 (07):
  • [9] ECONOMIC VALUE AND HEALTH SYSTEM IMPACT OF REMDESIVIR IN TREATING HOSPITALIZED COVID-19 PATIENTS IN THE UNITED STATES
    Sun, F.
    Jeyakumar, S.
    Smith, N.
    VALUE IN HEALTH, 2021, 24 : S10 - S10
  • [10] Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States
    Bode, Bruce
    Garrett, Valerie
    Messler, Jordan
    McFarland, Raymie
    Crowe, Jennifer
    Booth, Robby
    Klonoff, David C.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (04): : 813 - 821